FOLH1 and prostate cancer: In 1996, the U.S. FDA approved Indium-111 (111In)-capromab pendetide (Prostascint®, Cytogen Corporation, Princeton, NJ, USA), the first anti-PSMA radiolabeled monoclonal antibody for gamma-scintigraphy in patients with prostate cancer.